{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:21:14Z","timestamp":1790364074393,"version":"4.1.0"},"reference-count":11,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroepidemiology"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Background:  Guillain-Barr\u00e9 syndrome is an immune-mediated acute inflammatory polyneuropathy that is associated with various triggers, including certain infections and vaccines. It has been suggested that both SARS-CoV-2 infection and vaccination may be triggering factors for Guillain-Barr\u00e9 syndrome, but evidence remains equivocal. Here, we conducted a population-based incidence study of Guillain-Barr\u00e9 syndrome spanning the 3 years immediately prior to and the 2 years during the pandemic.   Methods:  Cases were identified by searching a regional diagnostic database for the ICD-10 code for Guillain-Barr\u00e9 syndrome. Individuals who fulfilled the Brighton criteria for Guillain-Barr\u00e9 syndrome were included. Information on clinical presentation, laboratory values, and vaccination status were retrieved from medical records. We calculated the incidence immediately prior to and during the pandemic.   Results:  The Guillain-Barr\u00e9 syndrome incidence rate was 1.35\/100,000 person-years for the pre-pandemic period and 0.66\/100,000 person-years for the pandemic period (incidence rate ratio: 0.49; p = 0.003). Three cases were temporally associated with SARS-CoV-2 infection and 1 case each to the AstraZeneca and Pfizer-BioNTech COVID-19 vaccines.   Conclusions:  Our results show that the incidence of Guillain-Barr\u00e9 syndrome decreased during the pandemic. This is most likely due to decreased prevalence of triggering infections due to social restrictions. Our findings do not support a causal relationship between Guillain-Barr\u00e9 syndrome and COVID-19. <\/jats:p>","DOI":"10.1159\/000527726","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T22:00:34Z","timestamp":1668117634000},"page":"1-6","source":"Crossref","is-referenced-by-count":21,"title":["Decreased Incidence of Guillain-Barr\u00e9 Syndrome during the COVID-19 Pandemic: A Retrospective Population-Based Study"],"prefix":"10.1159","volume":"57","author":[{"given":"Brynhildur","family":"Hafsteinsd\u00f3ttir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Dalemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7444-725X","authenticated-orcid":false,"given":"\u00d3l\u00f6f","family":"El\u00edasd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00edas","family":"\u00d3lafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00339-1"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112795"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(20)30109-5"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.102"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324837"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa433"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12482"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac067"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.003"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(78)92644-2"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1023\/a:1007312112285"}],"container-title":["Neuroepidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ned\/article-pdf\/57\/1\/1\/3963792\/000527726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ned\/article-pdf\/57\/1\/1\/3963792\/000527726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:30:23Z","timestamp":1745422223000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000527726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,22]]},"published-print":{"date-parts":[[2023,3,28]]}},"URL":"https:\/\/doi.org\/10.1159\/000527726","archive":["Portico"],"relation":{},"ISSN":["0251-5350","1423-0208"],"issn-type":[{"value":"0251-5350","type":"print"},{"value":"1423-0208","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]}}}